Staten was founded by Prof. Alan Tall, Prof. Daniel Rader, and Dr. Paul da Silva Jardine with the goal of developing novel therapies that address cardiovascular disease and prevent cardiovascular events. Staten is incorporated in the Netherlands with R&D operations in the US. The company is managed by a highly experienced team and is supported by world-renowned key opinion leaders in dyslipidemia and cardiovascular disease.